GlobeNewsWire
12 Jan 2026, 13:30 UTC · 36w ago
Verdict
Headline takes no side. We score MBOT +0.90 across three claims — strongly bullish.
+0.90strongly bullish
More positive than 96% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Microbot Medical plans a Full Market Release (FMR) of the LIBERTY Endovascular Robotic System in Q2 2026.
More positive than 99% of claims this week
The LIBERTY system has already received FDA 510(k) clearance and has been adopted by its first customer for patient care.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 93% of claims this week
The company is targeting a U.S. market of 2.5 million peripheral endovascular procedures annually.
More positive than 78% of claims this week
Which stocks this story touches
More positive than 96% of ticker scores this week
The company achieved FDA clearance, initiated limited market release of its LIBERTY system, and reported positive customer feedback.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
17h ago
−39.0%
Price is moving against the score
$1.27 vs $2.09 close before publication (Jan 9) · not market-adjusted
MBOT chart →
